> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Expands Wegovy to Cardiovascular Risk Reduction After 17,604-Patient Trial Shows 20% Fewer Major Events
- URL: https://www.theamericanquorum.com/taq-historical-2024-03-09-healthcare/
- Published: 2024-03-10T04:59:00.000Z
- Updated: 2024-03-10T04:59:00.000Z
- Description: FDA expanded Wegovy’s label to reduce cardiovascular death, heart attack and stroke in adults with cardiovascular disease and overweight or obesity after SELECT showed a 20% reduction in major events.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-09-01 11:58

The Food and Drug Administration on Friday approved Wegovy, the obesity medicine semaglutide, to reduce the risk of cardiovascular death, heart attack and stroke in adults who already have cardiovascular disease and are overweight or obese. The decision makes Wegovy the first weight-management drug in the United States with an indication specifically tied to preventing major cardiovascular events in this population, broadening the clinical role of a medicine that has largely been discussed through the lens of weight loss.

The [FDA](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or?ref=theamericanquorum.com) said the new indication is based on a multinational, placebo-controlled trial of more than 17,600 participants. Major adverse cardiovascular events occurred in 6.5% of patients assigned to Wegovy and 8.0% assigned to placebo, a relative reduction of about 20%. Participants in both groups also received standard cardiovascular care and counseling on diet and physical activity.

## SELECT moves semaglutide beyond a weight-loss endpoint

The pivotal evidence comes from SELECT, a randomized, double-blind trial enrolling 17,604 adults at least 45 years old who had established cardiovascular disease, a body-mass index of 27 or greater and no history of diabetes. The [New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563?ref=theamericanquorum.com) reported that 8,803 participants received once-weekly semaglutide 2.4 milligrams and 8,801 received placebo, with a mean treatment exposure of roughly 33 months.

The trial’s primary endpoint combined cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Semaglutide reduced that composite outcome with a hazard ratio of 0.80\. The [American College of Cardiology’s trial summary](https://www.acc.org/latest-in-cardiology/clinical-trials/2023/11/09/15/04/select?ref=theamericanquorum.com) reports event rates of 6.5% with semaglutide and 8.0% with placebo. Nonfatal myocardial infarction occurred less often in the semaglutide group, and all-cause mortality was also lower, although individual component outcomes varied in statistical strength.

The result is important because earlier cardiovascular benefits for GLP-1 receptor agonists were established largely in patients with type 2 diabetes. SELECT specifically enrolled people without diabetes, testing whether the drug could reduce the excess cardiovascular risk associated with obesity and overweight in patients who already had heart or vascular disease.

## A regulatory label can change how clinicians and insurers view obesity treatment

Wegovy was already approved for chronic weight management in certain adults and adolescents. The new indication changes the medical framing. Physicians treating a patient with prior myocardial infarction, stroke or peripheral arterial disease can now consider semaglutide not only as a treatment for excess weight but as an FDA-approved cardiovascular risk-reduction therapy when the patient also meets the overweight or obesity criteria.

Novo Nordisk said in its March 8 [approval announcement](https://www.prnewswire.com/news-releases/wegovy-receives-fda-approval-for-cardiovascular-risk-reduction-in-adults-with-known-heart-disease-and-overweight-or-obesity-302084454.html?ref=theamericanquorum.com) that Wegovy is now indicated both for long-term weight management and for reducing major cardiovascular events in adults with known heart disease and overweight or obesity. The company called SELECT the largest cardiovascular outcomes trial completed in people with obesity and established heart disease.

The expanded label could also affect insurance coverage. Federal law generally restricts Medicare coverage of drugs when they are used solely for weight loss, and many commercial insurers maintain their own limits on obesity medicines. A cardiovascular indication creates a different reimbursement question because the drug now has an approved use tied to preventing heart attack, stroke and cardiovascular death. [Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-novo-nordisks-wegovy-use-reducing-heart-attack-risks-2024-03-08/?ref=theamericanquorum.com) reported that clinicians and analysts expect the new indication to increase pressure on insurers to cover the medicine for eligible high-risk patients, even as cost and supply remain major constraints.

## The benefit comes with tolerability and safety limits

The cardiovascular result does not eliminate the drug’s known risks. The FDA label retains a boxed warning about thyroid C-cell tumors and cautions against use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\. Warnings also address pancreatitis, gallbladder disease, acute kidney injury, hypersensitivity, increased heart rate and suicidal behavior or thinking.

Tolerability was a meaningful issue in SELECT. The [American College of Cardiology](https://www.acc.org/Latest-in-Cardiology/Articles/2023/08/10/14/29/SELECT-Semaglutide-Reduces-Risk-of-MACE-in-Adults-With-Overweight-or-Obesity?ref=theamericanquorum.com) reported when the topline results were released that the study demonstrated a 20% reduction in major adverse cardiovascular events. In the fuller trial analysis, adverse events leading to discontinuation occurred more often with semaglutide, driven largely by gastrointestinal effects such as nausea, vomiting and diarrhea.

Those trade-offs matter because the eligible population could be large. The FDA estimates that roughly 70% of American adults are overweight or obese, although only a subset also has established cardiovascular disease and meets the label’s criteria. For clinicians, the practical decision will involve weighing cardiovascular benefit against tolerability, contraindications, patient preference, access and the need for long-term treatment.

## The approval strengthens the case that obesity is a cardiovascular treatment target

The SELECT findings challenge a longstanding separation between weight management and cardiovascular disease treatment. Patients in the trial were already receiving standard care for blood pressure, cholesterol and other risk factors, yet semaglutide produced an additional reduction in major events. The mechanism may involve several effects at once, including weight loss, blood-pressure reduction, changes in inflammation, metabolic effects and pathways not fully explained by the trial.

The [Associated Press](https://apnews.com/article/ccbc1fc44ee43f8536596d5f7bbd6876?ref=theamericanquorum.com) reported that the FDA decision could reshape how physicians and payers think about obesity medicines because the approval is linked to a hard clinical outcome rather than weight alone. That distinction is central to the importance of Friday’s action: preventing heart attack or stroke carries a different medical and economic argument than reducing pounds on a scale.

At the same time, the evidence applies to a defined population, not everyone seeking weight loss. SELECT participants had established cardiovascular disease before enrollment and were overweight or obese but did not have diabetes. The trial does not establish identical cardiovascular benefit for lower-risk patients who have not already experienced cardiovascular disease.

By Saturday, the FDA’s decision has therefore moved semaglutide into a new category of cardiovascular prevention. Wegovy remains an obesity drug, but its label now recognizes that treatment can produce a measurable reduction in life-threatening cardiovascular events among high-risk patients. For cardiology, primary care and obesity medicine, the next questions will be practical ones: which patients are most likely to benefit, how safely they can remain on therapy and whether coverage and manufacturing capacity can expand fast enough to match the population potentially eligible for treatment.